Metastatic Pancreatic Cancer

Oncology·MeSH: Pancreatic Neoplasms

Prevalence

8.0 / 100K

Incidence

13.1 / 100K/yr

12 drugs in development·10 companies·16 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
FOLFIRINOX	IGM Biosciences, Inc. (IGMS)
ivospemin	PANBELA THERAPEUTICS, INC. (SNBP)

Phase 2(4)

Drug	Company
ABV-1703	ABVC BIOPHARMA, INC. (ABVC)
folfirinox alone	Salspera, Inc. (TKVA)
nal-IRI,5-fu,LV, benmelstobart, anlotinib	Merus N.V. (MRUS)
salmonella-il2	Salspera, Inc. (TKVA)

Phase 1(1)

Drug	Company
APX005M	IGM Biosciences, Inc. (IGMS)

Preclinical(1)

Drug	Company
cypcaps	PharmaCyte Biotech, Inc. (PMCB)

Unknown(1)

Drug	Company
sm-88	TYME TECHNOLOGIES, INC. (TYME)

Phase 1/Phase 2(2)

Drug	Company
bpx-601	BELLICUM PHARMACEUTICALS, INC (BLCM)
son-1210	SONNET BIOTHERAPEUTICS HOLDINGS, INC. (BURG)

Phase 2/Phase 3(1)

Drug	Company
surufatinib combined with camrelizumab	HUTCHMED (China) Ltd (HMDCF)

BioSniper tracks 12 drugs in development for Metastatic Pancreatic Cancer across 10 companies.

There are 16 clinical trials targeting Metastatic Pancreatic Cancer tracked by BioSniper.

The estimated prevalence of Metastatic Pancreatic Cancer is approximately 8.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.